Hudson Bay Capital Management’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Hudson Bay Capital Management’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-99,999	Closed	-$1.01M	–	1176
2022 Q4	$1.01M	Hold	99,999	–	–	0.01%	690
2022 Q3	$992K	Hold	99,999	–	–	0.01%	845
2022 Q2	$978K	Hold	99,999	–	–	0.01%	938
2022 Q1	$974K	Hold	99,999	–	–	0.01%	831
2021 Q4	$969K	Hold	99,999	–	–	0.01%	808
2021 Q3	$967K	Hold	99,999	–	–	0.01%	756
2021 Q2	$966K	Buy	+99,999	New	+$982K	0.01%	743

Hudson Bay Capital Management's EBAC Position: Q1 2023 in Review

Hudson Bay Capital Management sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q1 2023, closing a stake of 99,999 shares — an estimated $1.01M sold.

Hudson Bay Capital Management first reported a position in EBAC in Q2 2021 and held it in 7 quarters. The position peaked at $1.01M in Q4 2022. 0 funds tracked by Wall St. Rank hold EBAC as of Q1 2023.

Hudson Bay Capital Management reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Hudson Bay Capital Management sold 99,999 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q1 2023, an estimated $1.01M.
Hudson Bay Capital Management first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q2 2021 and held it in 7 quarters.
Hudson Bay Capital Management's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $1.01M in Q4 2022.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q1 2023.

Based on Hudson Bay Capital Management's 13F filing for Q1 2023, filed 15 May 2023.